Drug shows promise in animal model of Alzheimer's and Parkinson's with dementia

New research presented in October at the 6th Neurodegenerative Conditions Research and Development Conference in San Francisco demonstrates the role of the investigational compound IRX4204 in alleviating cognitive decline in animal models of Alzheimer's disease (AD). The presentation entitled "Investigation of the RXR-specific agonist IRX4204 as a Disease Modifying Agent of Alzheimer's Disease Neuropathology and Cognitive Impairment" was made by lead researcher Giulio Maria Pasinetti, MD, PhD, of the Mount Sinai School of Medicine in New York City.

IRX4204 is a retinoid X receptor (RXR) agonist, meaning it stimulates the retinoid receptor in the brain.The data demonstrates attenuation of AD including prevention of plaque deposits associated with in an IRX4204-treated mouse model genetically determined to develop AD. IRX4204 also prevents neuropathological features associated with abnormal tau processing, another form of also found in a form of Parkinson's disease associated with dementia.

"The treatment of AD remains a serious unmet medical need which IRX4204 may be able to address," Dr. Pasinetti said "Our research show that IRX4204 and other RXR agonists have potential for slowing, and possibly reversing pathology and cognitive deficits in Alzheimer's disease patients."

Ongoing translational studies in subjects with Alzheimer's disease and Parkinson's disease with dementia are currently being developed.

Alzheimer's disease currently afflicts more than 5 million Americans and may triple in prevalence to more than 16 million Americans by 2050, according to data from The Alzheimer's Association.

Related Stories

Study finds certain drugs cut Alzheimer's

date Dec 06, 2006

U.S. scientists say they've identified anti-hypertensive agents that can prevent cognitive decline and amyloid neuropathology in Alzheimer patients.

A 'grape' future for Alzheimer's disease research

date Nov 06, 2007

With National Alzheimer’s Awareness Month upon us, attention continues to focus on new approaches to cognitive health in an aging population. Now, research with grape polyphenols presented today at Neuroscience 2007 in ...

Recommended for you

Volunteers in Tunisia develop app for Alzheimer's patients

date 10 hours ago

About a year ago, Azer Jaafoura and a few of his colleagues at Samsung Electronics Tunisia (SETN) were thinking of helping out Alzheimer's patients. However, with a full-time job and already volunteering at a children's hospital, ...

Helpful app for people with dementia

date Apr 21, 2015

Bangor University is providing expertise to support the development and effectiveness of 'Book of You', an 'app' being welcomed as having the potential to revolutionise reminiscence therapy for people with dementia.

New approaches for early diagnosis of Alzheimer's

date Apr 17, 2015

Mild cognitive impairment, or MCI, may be one of Alzheimer's earliest signs. The subtle changes of MCI include problems with memory, language, thinking and judgment and a subjective sense that mental function ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.